Global CRM197 麻豆原创 Research Report 2023

Publication ID:

PB501231237

Publication Date:

January 12, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

CRM197 is a non-toxic mutant of diphtheria toxin and it's widely used as a carrier protein for conjugate vaccines.
Highlights
The global CRM197 market was valued at US$ 177.1 million in 2022 and is anticipated to reach US$ 240.8 million by 2029, witnessing a CAGR of 5.3% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Pfizer Inc is one of the most important global manufacturers of CRM197, holds a share of over 85%. North America is the largest market, occupied for over 75%. In terms of type, research grade is the largest segment, with a share of over 85%. And in terms of application, pneumococcal conjugate vaccine segment holds a share of about 90%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CRM197, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CRM197.
The CRM197 market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global CRM197 market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CRM197 companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer Inc.
Ligand Pharmaceuticals
CanSino Biologic
Beijing Kexing Biology Product
Scarab Genomics
Xpress Biologics
Fina Biosolutions
Eubiologics
EirGenix Inc.
Segment by Type
Research Grade CRM197
cGMP Grade CRM197
Segment by Application
Pneumococcal Conjugate Vaccine
Meningococcal Polysaccharide Conjugate Vaccine
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CRM197 companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global CRM197 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Research Grade CRM197
1.2.3 cGMP Grade CRM197
1.3 麻豆原创 by Application
1.3.1 Global CRM197 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pneumococcal Conjugate Vaccine
1.3.3 Meningococcal Polysaccharide Conjugate Vaccine
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CRM197 麻豆原创 Perspective (2018-2029)
2.2 CRM197 Growth Trends by Region
2.2.1 Global CRM197 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 CRM197 Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 CRM197 Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 CRM197 麻豆原创 Dynamics
2.3.1 CRM197 Industry Trends
2.3.2 CRM197 麻豆原创 Drivers
2.3.3 CRM197 麻豆原创 Challenges
2.3.4 CRM197 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top CRM197 Players by Revenue
3.1.1 Global Top CRM197 Players by Revenue (2018-2023)
3.1.2 Global CRM197 Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global CRM197 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CRM197 Revenue
3.4 Global CRM197 麻豆原创 Concentration Ratio
3.4.1 Global CRM197 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CRM197 Revenue in 2022
3.5 CRM197 Key Players Head office and Area Served
3.6 Key Players CRM197 Product Solution and Service
3.7 Date of Enter into CRM197 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 CRM197 Breakdown Data by Type
4.1 Global CRM197 Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global CRM197 Forecasted 麻豆原创 Size by Type (2024-2029)
5 CRM197 Breakdown Data by Application
5.1 Global CRM197 Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global CRM197 Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America CRM197 麻豆原创 Size (2018-2029)
6.2 North America CRM197 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CRM197 麻豆原创 Size by Country (2018-2023)
6.4 North America CRM197 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CRM197 麻豆原创 Size (2018-2029)
7.2 Europe CRM197 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CRM197 麻豆原创 Size by Country (2018-2023)
7.4 Europe CRM197 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CRM197 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific CRM197 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CRM197 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific CRM197 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CRM197 麻豆原创 Size (2018-2029)
9.2 Latin America CRM197 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CRM197 麻豆原创 Size by Country (2018-2023)
9.4 Latin America CRM197 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CRM197 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa CRM197 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CRM197 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa CRM197 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Detail
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. CRM197 Introduction
11.1.4 Pfizer Inc. Revenue in CRM197 Business (2018-2023)
11.1.5 Pfizer Inc. Recent Development
11.2 Ligand Pharmaceuticals
11.2.1 Ligand Pharmaceuticals Company Detail
11.2.2 Ligand Pharmaceuticals Business Overview
11.2.3 Ligand Pharmaceuticals CRM197 Introduction
11.2.4 Ligand Pharmaceuticals Revenue in CRM197 Business (2018-2023)
11.2.5 Ligand Pharmaceuticals Recent Development
11.3 CanSino Biologic
11.3.1 CanSino Biologic Company Detail
11.3.2 CanSino Biologic Business Overview
11.3.3 CanSino Biologic CRM197 Introduction
11.3.4 CanSino Biologic Revenue in CRM197 Business (2018-2023)
11.3.5 CanSino Biologic Recent Development
11.4 Beijing Kexing Biology Product
11.4.1 Beijing Kexing Biology Product Company Detail
11.4.2 Beijing Kexing Biology Product Business Overview
11.4.3 Beijing Kexing Biology Product CRM197 Introduction
11.4.4 Beijing Kexing Biology Product Revenue in CRM197 Business (2018-2023)
11.4.5 Beijing Kexing Biology Product Recent Development
11.5 Scarab Genomics
11.5.1 Scarab Genomics Company Detail
11.5.2 Scarab Genomics Business Overview
11.5.3 Scarab Genomics CRM197 Introduction
11.5.4 Scarab Genomics Revenue in CRM197 Business (2018-2023)
11.5.5 Scarab Genomics Recent Development
11.6 Xpress Biologics
11.6.1 Xpress Biologics Company Detail
11.6.2 Xpress Biologics Business Overview
11.6.3 Xpress Biologics CRM197 Introduction
11.6.4 Xpress Biologics Revenue in CRM197 Business (2018-2023)
11.6.5 Xpress Biologics Recent Development
11.7 Fina Biosolutions
11.7.1 Fina Biosolutions Company Detail
11.7.2 Fina Biosolutions Business Overview
11.7.3 Fina Biosolutions CRM197 Introduction
11.7.4 Fina Biosolutions Revenue in CRM197 Business (2018-2023)
11.7.5 Fina Biosolutions Recent Development
11.8 Eubiologics
11.8.1 Eubiologics Company Detail
11.8.2 Eubiologics Business Overview
11.8.3 Eubiologics CRM197 Introduction
11.8.4 Eubiologics Revenue in CRM197 Business (2018-2023)
11.8.5 Eubiologics Recent Development
11.9 EirGenix Inc.
11.9.1 EirGenix Inc. Company Detail
11.9.2 EirGenix Inc. Business Overview
11.9.3 EirGenix Inc. CRM197 Introduction
11.9.4 EirGenix Inc. Revenue in CRM197 Business (2018-2023)
11.9.5 EirGenix Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer Inc.
Ligand Pharmaceuticals
CanSino Biologic
Beijing Kexing Biology Product
Scarab Genomics
Xpress Biologics
Fina Biosolutions
Eubiologics
EirGenix Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.